Argenx makes $2.2B move for Forte Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 27 July, 2026

sponsored by Medicine is a national security asset. America wins by building, not retreating. Adversary states are investing to control the biopharmaceutical capacity that national security now depends on. China already hosts 39 percent of the world's clinical trials. America cannot afford to surrender leadership of this strategic industry. But tariffs, decoupling, and blanket bans are not toughness. They are retreat. America wins by building capacity at home and with trusted allies, and by out-competing rivals instead of hiding from them. See where we stand

SPOTLIGHT In Focus Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs

news AstraZeneca’s pipeline struggles continue as it reports disappointing data in cancer, rare disease •  AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B Exclusive: Schrödinger CEO 'couldn't be more pleased to be wrong' in launch of AI agent Bunsen

Jul 30 1:00 pm ET Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights sponsored by GUARDANT Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM

Associate Director / Director, Preclinial Development - Immunology Terray Therapeutics, Inc. Monrovia, CA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Machine Learning Researchers and Engineers D. E. Shaw Research New York, NY, USA Scientist, Drug Discovery Data for AI/ML D. E. Shaw Research New York, NY, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.

ENDPOINTS PHARMA CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa Amgen shares new analysis with FDA in bid to keep Tavneos on the market Updated: FDA adcomm backs popular wellness peptides, despite staff concerns

in case you missed it 1. Ipsen’s Bylvay fails key trial in children with rare liver disease 2. Peer Review Michael Ehlers joins Formation Bio to lead R&D; Black Diamond co-founder dies at 67 3. News Briefing